Downregulation of Mir-129-2 by Promoter Hypermethylation Regulates Breast Cancer Cell Proliferation and Apoptosis.

Xiaofeng Tang,Jianjun Tang,Xia Liu,Lei Zeng,Chun Cheng,Yanqin Lu,Liping Li,Shu-Lan Qin,Yi Sang,Liang-Ming Deng,Xiao-Bin Lv
DOI: https://doi.org/10.3892/or.2016.4647
2016-01-01
Oncology Reports
Abstract:Aberrant expression of the miR-129 family has been found in several types of cancer, yet its expression and potential biologic role in breast cancer remain largely unknown. In the present study, we found that miR-129-2 was consistently downregulated in the breast cancer specimens and cell lines. Overexpression of miR-129-2-3p markedly suppressed breast cancer cell proliferation and induced its apoptosis. In addition, a luciferase reporter assay revealed that miR-129-2-3p suppressed BCL2L2 expression. Furthermore, BCL2L2 was able to reverse miR-129-2-3p-mediated cell apoptosis, indicating that BCL2L2 plays a crucial role in mediating the tumor-suppressive role of miR-129-2-3p. Moreover, bisulfite DNA sequencing PCR (BSP) analysis identified that promoter hypermethylation was responsible for the downregulation of miR-129-2 in breast cancer. Collectively, our findings indicate that miR-129-2 is downregulated in breast cancer cells by promoter hypermethylation. Moreover, downregulation of miR-129-2 results in BCL2L2 overexpression and disease progression in breast cancer patients.
What problem does this paper attempt to address?